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ABSTRACT 
 
Background: Erectile function is an important factor for all men in an active sexual condition, as 
well as to assess the quality of sex life with their partners. Transurethral Resection of the Prostate 
(TURP) is a gold standard action for Benign Prostate Hyperplasia (BPH). The researcher tried to 
study to investigate the effect of corticosteroid and progesterone on erectile function in BPH 
patients who have done TURP surgery by using Erection Hardness Score (EHS). The purpose of 
this study was to investigate the effect of intra venous methylprednisolone on post-operative 
erection function of TURP in BPH patients. To investigate the effect of intra-muscular 
progesterone on postoperative erectile function of TURP in BPH patients. To investigate the 
different effect between methylprednisolone and progesterone on post-operative erection function 
of TURP in BPH patients. 
Subjects and Method: Subjects of all BPH patients who performed TUR-P surgery in the 
urology sub-section of Dr. Moewardi Hospital, Surakarta. The sampling technique in this study was 
incidental sampling. This study was a clinical experimental study using Pre and Post-test design-
Only Control Design. 3 groups were divided to get different treatment, the first group was given 
methylprednisolone, the second group was given progesterone and the third group was given 
TURP therapy protocol only. 
Results: After 1 month of TURP treatment in BPH patients, the result obtained for the EHS which 
on a scale of 2 and 3. EHS on scale 2 for the methylprednisolone group was 9 patients (69.2%), the 
progesterone group had 6 patients (46.2%), and the control group had 8 of patients (66.7%). 
Meanwhile, EHS on scale 3 for the methylprednisolone group was 4 patients (30.8%), there were 7 
patients (53.8%) of the progesterone group, and the control group had 4 patients (33.3%). After 3 
months of TURP treatment in BPH patients, EHS on scale 2 in the methylprednisolone group there 
were 2 patients (15.4%), the progesterone group there were 0 patients (0.0%), and the control 
group there were 6 patients (50.0%). The methylprednisolone group had 9 patients (69.2%) on 
EHS 3 scale, the progesterone group had 4 patients (30.8%), and there were 6 patients (50.0%) in 
the control group. While, EHS scale of 4 the total of the patients in the methylprednisolone group 
was 2 patients (15.4%), the progesterone group had 9 patients (69.2%), and the control group had 0 
patients (0.0%). 
Conclusion: the methylprednisolone improved the erectile function in post-operative TURP 
patients. Progesterone improved erectile function in post-operative TURP patients. Therefore, it 
can be concluded that progesterone was better than methylprednisolone. 
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BACKGROUND 
Erectile function is an important factor for 
all men in an active sexual condition, as 
well as to assess the quality of sex life with 
their partners. The higher the level of 
erection hardness is, the higher the sexual 
satisfaction is and it could improve the 
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whole quality of life (Goldstein et al., 1998; 
Mulhall, 2008). 
 According to the United States 
National Institutes of Health and the 
American Urological Association, Erectile 
Dysfunction (ED) is defined as the inability 
to achieve or maintain an adequate erection 
for sexual satisfaction. According to the 
International Journal of Impotence Study 
(IJIR) in 2013, the effect of TURP on 
erectile function is still controversial and 
the available data is still under debate. 
 Transurethral Resection of the 
Prostate (TURP) is a gold standard action 
for Benign Prostate Hyperplasia (BPH). 
One of the complications after surgery that 
can be generated after the patient gets the 
action is DE (Thorpe et al, 1999; Florator et 
al 2001). Some patients suffer temporary 
ED right after TURP and the returning of 
erection ability with ranges from 1 to 6 
months right after TURP. The effects of ED 
for in patients right after TURP are still 
controversial, one of the possible causes of 
ED is the result of heat trauma to the 
erectile nerves (Jaidane 2010; Poulakis et 
al, 2006). 
 Corticosteroid has anti-inflammatory 
and immunosuppressive effects by 
decreasing the coming out cells and the 
function of inflammatory cells and the 
permeability of blood vessels in the 
inflammatory part. Corticosteroid also 
inhibits the synthesis of prostaglandins and 
leukotrienes by inhibiting the release of 
arachidonic acid from phospholipids. With 
this mechanism, corticosteroids protects 
organs from damage (Priyanka et al, 2008). 
 Some journals mention the 
mechanism of progesterone. It has a 
protective effect on peripheral nerves. Its 
action mechanism is an example of a 
regulation of neurotropin expression which 
is able to help cells survive. In addition, 
main metabolic outcomes of progesterone 
such as allopregnanolone are reported 
taking a part in neuroprotective effects. 
 
SUBJECTS AND METHOD 
1. Study design/ the design of the 
study 
This study is a clinical experimental study 
using Pre and Post-test design-Only 
Control Design. In this design, the subjects 
were divided into 3 groups, the first group 
was given the TURP + methylprednisolone 
therapy protocol, the second group was 
given the TURP + progesterone therapy 
protocol, and the third group was given 
TURP therapy protocol only. Then, that will 
be assessed before TURP during 1 to 3 
months after TURP assessed erectile 
function before TURP, 1 month and 3 
months after TURP by using Erection 
Hardness Score (EHS). 
 The study was conducted in the sub-
section of urology Section RSDM Surakarta, 
started in December 2016 - May 2017. The 
population of this study were all BPH 
patients who have done TUR-P surgery in 
the sub-section of urology RSUD Dr. 
Moewardi Surakarta. 
2. Population and sample 
The sampling technique in this study was 
incidental sampling. The subject size was 
determined by using the subject formula for 
a cross-sectional study (a single subject to 
test the hypothesis of a population) that is: 
 
𝑛 =
(
𝑍α
2
+ Zβ P. Q
(𝑃 −
1
2
)
 
 
𝑛 =  
(1,96 + 80% 0,75𝑋0,25
 0,75 − 0,5 
 
 
𝑛 =  38 
 
Information: 
N: Minimum number of subjects required 
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Zα: 95% confidence level  Z = 1.96 
Zβ: Power 80% 
P: R / (1 + R) 
Q: 1 - P8 
R: Estimated Odds Ratio = 3 
Restriction Criteria: 
1. Inclusion criteria 
a. The BPH diagnosed patients and post-
TURP surgery 
b. BPH patients between the range of 50 
and 70 years 
c. Patients are willing to attend study and 
fill out informed consent 
d. BPH patients with normal erectile 
function before TURP. 
2. Exclusion criteria 
a. Patients of BPH who have done previous 
TURP surgery 
b. Patients suspected of prostate cancer 
c. BPH patients with a history of erectile 
dysfunction prior to TURP surgery 
d. BPH patients with diseases: 
 1) Hypertension 
 2) Diabetes mellitus 
 3) Heart failure 
 4) Stroke 
 5) Spinal Trauma 
3. Data Analysis 
The analytical test was implemented in this 
study, because comparing 3 different 
groups which are independent each other 
and the scale of variable data measured on 
a nominal scale, thus  v the statistical test 
used was Kruskal Wallis test. 
 
RESULTS 
The age of the patients given the 
intervention of Metilprednisolon was 
averaged 65.00 + 3.94 years, meanwhile 
the age of the patients given the Proges-
terone intervention averaged 61.85 + 5.63 
years, and the patient age in the control 
group averaged 64.83 + 3.27 years, the 
value (p> 0.05) there is no significant 
difference. 
 The prostate volumes before TURP in 
patients who have been given the 
intervention of methylprednisolone was 
averaged 58.00 + 7.56 g, while patients 
given an average Progesterone intervention 
was 58.60 + 8.17 g, and the patients in the 
control group were 58.00 + 7.54, the score 
(p>0.05). 
 TURP prostate volumes in patients 
with methylprednisolone intervention were 
on averaged 51.54 + 8.99 g, while non-
methylprednisolone patients were an 
average progesterone intervention were 
51.92 + 8.55 g, and the patients in the 
control group were averaging 50.00 + 7.39, 
> 0.05). 
Table 1. characteristics of BPH patients  
Variable 
Intervention 
p 
Methylprednisolone Progesterone Control 
Age  65.00 + 3.94 61.85 + 5.63 64.83 + 3.27 0.103 
Prostat Volume  58.00  + 7.56 58.60 + 8.17 58.00 + 7.54 0.971 
Prostat TURP Volume 51.54 + 8.99 51.92 + 8.55 50.00 + 7.39 0.806 
Note: Kruskal Wallis test (numerical data is not normally distributed) 
   
Before the TURP action on the 4th (entirely 
hard and fully strained) EHS BPH patient 
in the methylprednisolone group there were 
8 patients (61.5%), the progesterone group 
had 9 patients (69.2%), there were 7 
patients (58.3 %) in the control group. 
While the rest were on a scale of 3 (hard 
enough for penetration but not completely 
hard) is in the methylprednisolone group 
which the total patients were 5 patients 
(38.5%), there were 4 patients (30.8%) in 
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the progesterone group, and there were 7 
patients (41.7%) in the control group. 
 After 1 month of TURP treatment in 
BPH patients, EHS was on a scale of 2 
(hard, but not hard enough for penetration) 
and 3 (hard enough for penetration but not 
completely hard). EHS met on scale 2 in the 
methylprednisolone group which was 9 
patients (69.2%, the progesterone group 
obtained 6 patients (46.2%), the control 
group had 8 patients (66.7%). While EHS 
was on scale 3, the methylprednisolone 
group obtained 4 patients (30.8%), the 
progesterone had 7 patients (53.8%), and 
there were 4 patients (33.3%) in the control 
group. 
Table 2. Differences erectile function before and after TURP action in BPH 
patients between Methylprednisolone, progesterone and control group 
EHS Scale 
Intervention 
p 
Methylprednisolone Progesterone Control 
Before Scale 1 0 (0.0%) 0(0.0%) 0 (0.0%)  0.847 
 
Scale 2 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 
 
Scale 3 5 (38.5%) 4 (30.8%) 5 (41.7%) 
   Scale 4 8 (61.5%) 9 (69.2%) 7 (58.3%)   
1 month Scale 1 0 (0.0%) 0 (0.0%) 0 (0.0%)  0.432 
 
Scale 2 9 (69.2%) 6 (46.2%) 8 (66.7%) 
 
 
Scale 3 4 (30.8%) 7 (53.8%) 4 (33.3%) 
   Scale 4 0 (0.0%) 0 (0.0%) 0 (0.0%)   
3 months Scale 1 0 (0.0%) 0 (0.0%) 0 (0.0%) <0.001 
 
Scale 2 2 (15.4%) 0 (0.0%) 6 (50.0%) 
 
 
Scale 3 9 (69.2%) 4 (30.8%) 6 (50.0%) 
   Scale 4 2 (15.4%) 9 (69.2%) 0 (0.0%)   
1vs3 month p** 0.003 0.001 0.157  
1. Note: * Unpaired group difference test; Kruskal Wallis (ordinal categorical data) 
2. ** Pair group differential test; Wilcoxon (ordinal categorical data) 
 
After 3 months of TURP action in BPH 
patients, EHS is on a scale 2 (hard, but not 
hard enough for penetration) and 3 (hard 
enough for penetration but not completely 
hard) and 4 (completely hard and fully 
strained) which is the methylprednisolone 
group had 2 patients (15.4%), the 
progesterone group obtained 0 patients 
(0.0%), and the control group had 6 
patients (50.0%). 
 
 Before TURP 
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Patients were on scale 3 of EHS in the 
methylprednisolone group as many as 9 
patients (69.2%), the progesterone group 
were 4 patients (30.8%), and the control 
group were 6 patients (50.0%). While 
patients were with EHS scale of 4 in the 
methylprednisolone group 2 patients 
(15.4%), the progesterone group obtained 9 
patients (69.2%), and the control group 
obtained 0 patients (0%). 
 
 
 
 
 
Picture 1. Comparison of erection function before and after 
TURP treatment for patients between the Methylprednisolone group, 
Progesterone, and Control 
 
DISCUSSION 
Based on the description above, it can be 
seen that BPH patients who got TURP 
treatment has the same conditions both 
from age and prostate volume before and 
after TURP treatment. The patients from 
these three treatments has decreased 
prostate volume after TURP action. Thus 
the patients’ characteristic data among the 
methylprednisolone, progesterone, and 
control groups were not significantly 
diffirent or homogeneous. 
1 Month after 
TURP 
3 Months after 
TURP 
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 As it is known that TURP is the 
standard gold for surgery action for BPH. 
However, this action can cause erectile 
dysfunction that will be suffered by the 
patients. The previous studies have stated 
that erectile dysfunction is between 4% and 
40%. A big difference in numbers can be 
caused due to the method used to assess the 
DE or the length of time the follow-up 
performed by the researcher. A number of 
patients had temporary DE post TURP and 
restored erection ability post TURP in 6 
months (Taher, 2004; Poulakis et al. 2006). 
The cause of DE post-TURP is not known 
for certain, but it is estimated to be due to 
neurovascular bundle damage due to heat 
trauma when the treatment is on process 
(Taher, 2004; Poulakis et al., 2006). 
 The results showed that methyl-
prednisolone and progesterone were effect-
tive in improving erectile dysfunction 
which was suffered by BPH patients who 
got TURP treatment. For the methyl-
prednisolone group, the ratio of erectile 
function between  1 month after TURP and 
3 months after TURP get the result of 
wilcoxon test with value (p <0.05) which 
means there is a significant difference of 
erection function between 1 month and 3 
months after TURP, so there was a 
significant improvement in the methyl-
prednisolone group. Hence, the hypothesis 
(H1) which states "There is an effect of intra 
venous methylprednisolone on post-
operative erection function of TURP in 
BPH patients. The giving of methyl-
prednisolone will improve the erection 
function of post-operative TURP patients 
"proven. 
 The comparison of erectile function 
between 1 month and 3 months after TURP 
in progesterone group got wilcoxon test 
result with value (p <0.05) which means 
there is significant difference of erection 
function between 1 month and 3 months 
after TURP, thus there is improvement 
which is significant in the progesterone 
group. Thus the hypothesis (H2) states 
"There is an effect of intra muscular proges-
terone on postoperative erectile function of 
TURP in BPH patients. 
The giving of progesterone will improve the 
erectile function in patients post-TURP 
surgery” proven. 
 Progesterone is more effective than 
methylprednisolone in improving erectile 
function. After 3 months of TURP treat-
ment in patients with BPH erectile function 
(EHS) in the majority group of methyl-
prednisolone on scale 3, there were 9 
patients (69.2%), in the majority proges-
terone group with scale 4, there were 9 
patients (69.2%), and the control group had 
6 patients (50.0%) with the scale of 2 and 3. 
Kruskal wallis’ statistical results obtained 
values (p <0.05), meaning that there was a 
significant difference in erectile function 3 
months after TURP action in BPH patients 
between methylprednisolone, progesterone, 
and control. As it can be seen that the 
progesterone group is better than methyl-
prednisolone and control group, and 
methylprednisolone is better than control 
group. Thus the hypothesis H3 which states 
"There is a difference in the effect of 
intravenous and progesterone methylpred-
nisolone on post-operative erection func-
tion of TURP in BPH patients. Proges-
terone is better than methylprednisolone. 
"Proven. 
 Methylprednisolone is a class of syn-
thetic steroids derived from glucocorticoid 
that has biological activity to reduce anti-
inflammatory effects after lesions (Nash et 
al., 2002). By inhibiting the production of 
various inflammatory materials such as 
chemotaxis, lysosomal enzyme, inhibiting 
an enzyme phospholipase A’s activity, the 
next will lead to decrease in arachidonic 
acid cascade metabolite production, then 
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decrease free radical formation, decrease 
TNF-α expression, decrease activity of 
nuclear factor that will decrease inflamma-
tory response. 
 Whereas progesterone is known 
produced in the central nervous system and 
the peripheral nervous system, and is 
considered as a neurosteroid. The responsi-
ble enzyme in progesterone biosynthesis is 
localized in the glia and Schwann cells of 
the central nervous system. Progesterone 
biosynthesis occurs in the mitochondria, 
the synthesis of progesterone in the 
nervous system has an important role in the 
regulation of myelin formation and the 
modulation of GABA type A receptor 
function (Milani et al., 2010). The proges-
terone synthesis plays an important role in 
the regulation of myelin formation and the 
modulation of GABA type A receptor 
function. Progesterone stimulates myelini-
zation by stimulating activation of gene 
code expression for myelin protein trans-
cription and indirectly regulating myelin 
formation by influencing gene expression in 
neurons and supporting regeneration of 
neurons with some ways include: reducing 
inflammation, edema and apoptosis, by 
stimulating the life-enhancing neurons 
through the formation of new myelin 
sheaths (Milani et al., 2010). 
 Based on the description above, it can 
be seen that giving intra vena methyl-
prednisolone and progesterone effect on 
erection function post-surgery TURP in 
BPH patients. Thus, progesterone is better 
than methylprednisolone. 
 Based on the results of the study 
which has been done on 38 patients with 
BPH treated in RSUD Dr Moewardi 
Surakarta and TURP surgery, it can be 
concluded as follows. Giving methylpred-
nisolone will improve the erection function 
of post-operative TURP patients. The giving 
of Progesterone improves the erectile 
function of patients with postoperative 
TURP. Thus, progesterone is better than 
methylprednisolone. 
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